No profile data available.
Milestone Pharmaceuticals Inc. (MIST) is a healthcare company in the cardiac treatment pharmaceuticals industry, based in Montreal, Canada, with about 38 full-time employees.
It reported revenue of $1.55 million for fiscal year 2025, and net income of -$63.06 million. Its market capitalization was $95.24 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. It offers CARDAMYST (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults.
Milestone Pharmaceuticals reported $1.55 million in revenue for fiscal year 2025.
$95.24 million as of October 9, 2026.
Listed companies of a similar size in the same industry (cardiac treatment pharmaceuticals) include Lexeo Therapeutics, Inc. (LXEO), Tenaya Therapeutics, Inc. (TNYA), Cardiol Therapeutics Inc. (CRDL), Windtree Therapeutics, Inc. (WINT).